Recruiting PHASE3 INTERVENTIONAL 2-arm NCT05696093

Efficacy of Cotrimoxazole as a De-escalation Treatment of Ventilator-Associated Pneumonia in Intensive Care Unit (COTRIVAP)

Efficacy of Cotrimoxazole as a De-escalation Treatment of Ventilator-Associated Pneumonia in Intensive Care Unit. Multicentric Non-inferiority Randomised Controlled Trial

Sponsor: Assistance Publique - Hôpitaux de Paris

Conditions Ventilator Associated Pneumonia

Interventions cotrimoxazole standard antibiotic therapy

Updated 2 times since 2024 Last updated: May 15, 2025 Started: Oct 19, 2023 Primary completion: Oct 31, 2026 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05696093, this PHASE3 trial focuses on Ventilator Associated Pneumonia and remains actively recruiting participants. Sponsored by Assistance Publique - Hôpitaux de Paris, it has been updated 2 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

2 versions recorded

Jun 2025 — Present [monthly]

Recruiting PHASE3
Sep 2024 — Jun 2025 [monthly]

Recruiting PHASE3

First recorded

Oct 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Assistance Publique - Hôpitaux de Paris

Data source: Assistance Publique - Hôpitaux de Paris

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amiens, France , Angers, France , Bobigny, France , Bordeaux, France , Boulogne-Billancourt, France , Béthune, France , Cholet, France , Clermont-Ferrand, France , Colombes, France , Corbeil-Essonnes, France and 18 more locations